Intus Bio
PrivateLast Round
Early Funding
Feb 14, 2018
Total Funding Raised
$1.85M
Company Overview
Intus Bio is a biotechnology company that provides an AI-powered platform, Titan-1™, for strain-level microbiome analysis and offers at-home gut health tests.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Precision Medicine, Healthcare Analytics, Drug Discovery, Medical AI
Business Model
B2B
Customer Profile
Services & Consulting, Hardware Sales, Government Contracts
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Intus Bio Comparables
Compare Intus Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Bio-Me AS | 81% | |
| Microba Life Sciences Ltd | 80% | |
| Clinical Microbiomics | 77% |
Intus Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Early Funding | Feb 14, 2018 | ||||
| Accelerator | Feb 2, 2018 | ||||
| Grant | Feb 1, 2018 | ||||
| Seed | Apr 21, 2017 | ||||
| Convertible Debt | Nov 9, 2016 | ||||
Pre Seed | Mar 11, 2016 |
Intus Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Connecticut Innovations | Seed, Early Funding, Pre Seed |
| UConn Innovation Fund | Seed |
| Accelerator for Biosciences in Connecticut | Accelerator |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jan 21, 2026
Monthly visitors grew 85% MoM, from 340 to 630.
- May 2, 2025
Monthly visitors grew 184% MoM, reaching 1.3K.
Recent news
Latest coverage and updates
- is_developingSep 11, 2026
Intus Biosciences, LLC develops a non-invasive screen for early-onset colorectal cancer with cancer researchers at four major institutions, using high-resolution bacterial microbiome discoveries, in Connecticut on Sep 11th '26.
- receives_financingSep 11, 2026
Intus Biosciences, LLC receives a $2.7M National Cancer Institute SBIR Fast-Track award on Sep 11th '26 in Connecticut to develop a non-invasive, bacteria-based screening test for early-onset colorectal cancer and precancerous lesions.
Intus Bio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Intus Bio's valuation, stock price, and market status.
Is Intus Bio a public or private company?
Intus Bio is a private company.
What is the current stock price of Intus Bio?
Intus Bio is a private company, so its shares have no public market price. Caplight tracks Intus Bio's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Intus Bio worth (valuation)?
Valuation information for Intus Bio is not publicly available.
Can I buy Intus Bio stock?
Intus Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Intus Bio's last funding round?
Intus Bio's most recent funding round was Early Funding on February 14, 2018.
Who are the main investors in Intus Bio?
Key investors in Intus Bio include Connecticut Innovations, UConn Innovation Fund, Accelerator for Biosciences in Connecticut.
Will Intus Bio IPO soon?
No public IPO plans have been announced for Intus Bio.
How can I track Intus Bio secondary market activity?
Caplight tracks bids, offers, and trades in Intus Bio's shares on secondary markets.